10x Genomics $TXG Shares Bought by Bayforest Capital Ltd

Key Points

• Bayforest Capital Ltd increased its position in 10x Genomics by 271.2% in Q2, acquiring a total of 94,864 shares valued at approximately $1,099,000.
• Institutional investors now own 84.68% of 10x Genomics’ stock, with several firms significantly increasing their holdings during the first quarter.
• Analysts have a mixed outlook on the stock, with a consensus target price of $13.65 and ratings ranging from "Strong Buy" to "Sell."

Bayforest Capital Ltd lifted its position in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 271.2% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 94,864 shares of the company's stock after purchasing an additional 69,306 shares during the quarter. 10x Genomics comprises approximately 0.5% of Bayforest Capital Ltd's holdings, making the stock its 25th largest holding. Bayforest Capital Ltd owned approximately 0.08% of 10x Genomics worth $1,099,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of TXG. GAMMA Investing LLC grew its holdings in shares of 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after purchasing an additional 1,614 shares during the period. Signaturefd LLC grew its holdings in shares of 10x Genomics by 134.3% during the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company's stock worth $37,000 after purchasing an additional 2,409 shares during the period. Whittier Trust Co. purchased a new stake in shares of 10x Genomics during the 1st quarter worth about $41,000. PNC Financial Services Group Inc. grew its holdings in shares of 10x Genomics by 153.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock worth $45,000 after purchasing an additional 3,119 shares during the period. Finally, US Bancorp DE grew its holdings in shares of 10x Genomics by 314.5% during the 1st quarter. US Bancorp DE now owns 5,973 shares of the company's stock worth $52,000 after purchasing an additional 4,532 shares during the period. Hedge funds and other institutional investors own 84.68% of the company's stock.

Analyst Ratings Changes

TXG has been the subject of a number of research reports. UBS Group boosted their target price on 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Piper Sandler assumed coverage on 10x Genomics in a report on Thursday, September 11th. They issued a "neutral" rating and a $15.00 price target for the company. Barclays restated an "overweight" rating and issued a $15.00 price target (up previously from $13.00) on shares of 10x Genomics in a report on Friday, August 8th. Canaccord Genuity Group set a $16.00 price target on 10x Genomics in a report on Monday, August 11th. Finally, Wall Street Zen upgraded 10x Genomics from a "hold" rating to a "buy" rating in a report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $13.65.

10x Genomics Trading Up 1.1%

TXG stock opened at $11.60 on Tuesday. The firm has a market cap of $1.44 billion, a P/E ratio of -16.57 and a beta of 2.05. 10x Genomics has a 12-month low of $6.78 and a 12-month high of $18.21. The stock's 50 day simple moving average is $12.94 and its 200 day simple moving average is $11.09.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.63. The business had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The business's revenue was up 12.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. On average, research analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other 10x Genomics news, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the sale, the insider directly owned 440,888 shares of the company's stock, valued at $6,079,845.52. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Adam Taich sold 22,315 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares in the company, valued at $4,264,874.67. This represents a 6.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,149 shares of company stock valued at $539,865 over the last three months. Company insiders own 10.03% of the company's stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.